drugset / Trial / NCT02809768
Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effects of concomitant administration with fluconazole, itraconazole, and rifampin on the pharmacokinetics (PK) of a single 20-mg dose of avatrombopag in healthy participants.
Timeline
- Start
- 2016-04
- Primary completion
- 2016-08
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 20 mg | Oral |
| Background | Fluconazole | Small molecule | 400 mg | Oral |
| Background | Itraconazole | Small molecule | 200 mg | Oral |
| Background | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.